Therapeutic Response

ER positive, ESR1 activating variants, and HER2-negative status confers therapeutic sensitivity to Camizestrant in combination with Palbociclib in patients with Invasive Breast Carcinoma.

Statements

Source and description

Etcamah (camizestrant) [product information]. EMA. The European Medicines Agency (EMA) has authorized camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1-mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor. The Product information further states that in pre- or perimenopausal women and in men, camizestrant plus a CDK4/6 inhibitor should be combined with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist.